Increased Interleukin-11 Levels Are Correlated with Cardiac Events in Patients with Chronic Heart Failure

Table 1

Information of clinical characteristics in the control and CHF group.

Characteristics	Control	CHF
		Total	NYHA II	NAHY III	NYHA IV
Age (years)	53 (42, 58)	63 (56, 72)	63 (58, 72)	63 (57, 68)	61 (52, 73)
Male (, %)	44 (55.0)	132 (55.0)	42 (60.0)	42 (55.3)	48 (51.1)
Smoking (, %)	24 (30.0)	63 (26.3)	16 (22.9)	20 (26.3)	27 (28.7)
BMI (kg/m^2)	24.7 (22.3, 27.3)	23.4 (21.6, 24.9)	24.1 (22.3, 25.3)	23.6 (22.4, 25.2)	22.4 (20.6, 24.5)^,#,†,§
HR (bpm)	72 (68, 75)	69 (63, 75)	69 (64, 75)	71 (63, 77)	68 (63, 73)
SBP (mmHg)	125 (116, 133)	115 (105, 125)	113 (106, 123)	115 (105, 124)	117 (105, 128)
DBP (mmHg)	78 (72, 84)	74 (66, 79)	71 (64, 78)	73 (67, 76)	75 (67, 82)^,†
TC (mmol/l)	4.2 (3.7, 4.7)	4.1 (3.5, 4.6)	4.1 (3.6, 4.6)	4.2 (3.6, 4.7)	4.1 (3.2, 4.5)^,§
TG (mmol/l)	1.1 (0.8, 1.4)	1.0 (0.8, 1.3)	0.9 (0.7, 1.1)	1.0 (0.8, 1.4)	1.0 (0.8, 1.5)^†
HDL-C (mmol/l)	1.0 (0.8, 1.3)	0.9 (0.8, 1.2)	1.0 (0.8, 1.2)	1.0 (0.8, 1.2)	0.9 (0.7, 1.1)
LDL-C (mmol/l)	2.0 (1.3, 2.5)	1.9 (1.4, 2.6)	1.9 (1.4, 2.3)	2.0 (1.4, 2.6)	1.9 (1.5, 2.6)
Glu (mmol/l)	5.3 (4.8, 6.0)	5.7 (4.9, 6.4)	5.2 (4.7, 6.1)^#	5.9 (4.9, 6.5)^,†	5.8 (5.0, 7.0)^,†
Albumin (g/l)	43 (39, 47)	39 (35, 41)	39 (35, 41)	39 (36, 41)	38 (35, 41)
CREA (μmol/l)	73 (64, 79)	92 (73, 124)	84 (68, 109)^,#	93 (73, 126)^,†	102 (82, 149)^,†
CRP (mg/l)	0.5 (0.3, 1.0)	7.4 (3.2, 15.3)	5.8 (2.7, 9.7)^,#	7.7 (3.3, 17.2)	11.3 (4.0, 18.3)^,†
NT-pro BNP (pg/ml)	89 (74, 101)	3633 (2400, 5235)	3290 (1725, 4562)^,#	3566 (2367,5220)	4138 (2528, 6236)^∗,#,†,§
LVEF (%)	61 (56, 64)	39 (35, 42)	41 (37, 43)	38 (35, 42)^,†	39 (35, 42)
LVEDD (mm)	47 (44, 50)	56 (52, 61)	53 (49, 57)^,#	56 (53, 61)^,†	56 (52, 63)^,†
DCM (, %)	-	68 (28.3%)	22 (31.4%)	20 (26.3%)	26 (27.7%)
IHD (, %)	-	78 (32.5%)	20 (28.6%)	28 (36.8%)	30 (31.9%)
HHD (, %)	-	62 (25.8%)	18 (25.7%)	20 (26.3%)	24 (25.3%)
Others (, %)	-	32 (13.3%)	10 (14.3%)	8 (10.5%)	14 (14.9%)
Medications, (, %)
ACEI/ARB	0 (0%)	162 (67.5%)	38 (54.3%)^#	52 (68.4%)	72 (76.6%)^§
β-Blockers	4 (5.0%)	92 (38.3%)	34 (48.6%)	38 (50.0%)	20 (21.3%)^#,§,†
Diuretics	0 (0%)	166 (69.2%)	34 (48.6%)^#	48 (63.2%)	84 (89.4%)^#,§,†
Digitalis	0 (0%)	166 (69.2%)	34 (48.6%)^#	48 (63.2%)	84 (89.4%)^#,§,†
Spironolactone	0 (0%)	118 (49.2%)	32 (45.7%)	28 (36.8%)^#,§	58 (61.7%)^#,§,†
Aspirin	8 (10%)	98 (40.8%)	22 (31.4%)	19 (23.7%)^#	58 (61.7%)^#,§,†
Statin	28 (35%)	72 (30.0%)	28 (40.0%)	20 (26.3%)	44 (46.8%)^#,†

BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: total triglycerides; HDL-C: high-density lipoprotein cholesterol; HDL-C: low-density lipoprotein cholesterol; Glu: fasting glucose; CREA: creatinine; CRP: C-reactive protein; NT-pro BNP: NT-pro brain natriuretic peptide; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic dimension; DCM: dilated cardiomyopathy; IHD: ischemic heart disease; HHD: hypertensive heart disease; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker. vs. the control group. vs. the total CHF group. vs. the NYHA II group. vs. the NYHA III group.